Manuscripts under the Special Issue are published under the theme "COMPLEMENTARY AND ALTERNATIVE THERAPEUTIC TECHNIQUES"

Guest Editor: Dr. S. Mohanasundaram
Assistant Guest Editors: Dr. S. Syed Abuthahir, Mrs. K. Geetha

INTERNATIONAL JOURNAL OF ZOOLOGICAL INVESTIGATIONS

Forum for Biological and Environmental Sciences
Published by Saran Publications, India
Psoriasis: A Comprehensive Review of Diagnosis and Treatment

Devinder Kumar Maheshwari¹, Hariharan S.², Krishna Prasanth B.², Rama Prasad Padhy³, Sagar Narendra Ande⁴, Poonam Popatrao Taru⁵, Darshan J.C.⁶, Muhammed Ameen M.P.⁶ and Dharmamoorthy G.⁷*

¹University College of Pharmacy, Guru Kashi University, Talwandi Sabo 151302, Punjab 151302, India
²Department of Community Medicine, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Chromepet, Chennai 44, Tamil nadu, India
³Danteswari College of Pharmacy, Borpadar, Raipur Road, Jagdalpur, Chhattisgarh 494221, India
⁴Dr. Rajendra Gode Institute of Pharmacy, Amravati 444602, India
⁵School of Pharmacy, Vishwakarma University, Kondhwa, Pune 411048, India
⁶Yenepoya Pharmacy College and Research Centre, Yenepoya Deemed to be University, Ayush Campus, Naringana, Mangaluru 575018, India
⁷MB School of Pharmaceutical Sciences (Erst while Sree Vidyanikethan College of Pharmacy) Mohan Babu University, Rangampeta, Tirupati 517102, India

*Corresponding Author

Received: 25th October, 2023; Accepted: 5th November, 2023; Published online: 4th December, 2023

https://doi.org/10.33745/ijzi.2023.v09ispl3.006

Abstract: Millions of people throughout the world suffer with psoriasis, a chronic inflammatory skin disorder that drastically lowers quality of life. This extensive overview explores the complex world of psoriasis and provides a thorough analysis of its diagnostic and treatment options. The review begins with an investigation of the psoriasis etiological variables, including genetic predisposition and environmental triggers. The clinical appearance of psoriasis is next explored, illuminating the several kinds and their distinctive clinical characteristics, ranging from the prevalent plaque psoriasis to the less common guttate and pustular varieties. The effectiveness of physical examination, medical history, and histological evaluations are discussed together with other closely examined diagnostic techniques. To give a thorough grasp of the signs and symptoms of the disease, a wide range of diagnostic methods are offered. This review's main emphasis is on the various psoriasis management strategies. These cover a broad range of therapeutic alternatives, such as topical medicines, phototherapy, systemic therapies, and new biologics. The study objectively assesses the effectiveness and safety profiles of each strategy, highlighting the necessity of individualized treatment regimens catered to patients' particular needs. This study emphasizes the value of comprehensive disease management measures, such as lifestyle changes, stress reduction, and psychological support, as crucial elements of psoriasis care in addition to therapy. The evaluation comes to a close by emphasizing the importance of patient education in enabling people to properly manage their conditions. Additionally, it addresses about current studies and advancements in the area, providing a view into how psoriasis may be identified and treated in the future. An in-depth analysis of psoriasis is provided in this thorough overview, along with helpful insights on how to diagnose it and the variety of potential treatments. It seeks to enhance clinical care and the general well-being of psoriasis sufferers by illuminating the complexity of this disorder.

Keywords: Phototherapy, Medical history, Histological evaluations, Psoriasis, Investigation, Pustular, Stress reduction, Lifestyle changes
People of all ages can have psoriasis, a persistent, non-infectious condition that has no preference for sex (Yin et al., 2019). It can affect the skin, nails, and joints and is associated with a variety of comorbidities. Psoriasis is a painful, debilitating, and disfiguring condition. The cause is still unknown, and the majority of treatments still focus on treating the acute symptoms. Psoriasis patients are more prone to develop depression, metabolic syndrome, diabetes, and cardiovascular diseases (Augustin et al., 2010). Depending on hereditary and environmental variables, concomitant diseases, drugs, and immune function, psoriasis exhibits a wide range of morphologic manifestations. Approximately 80% of all instances of psoriasis are of the plaque-type, making it the most common kind. Plaque psoriasis is a very noticeable condition marked by clearly defined, thick, red, itchy lesions that are coated in silvery scales. The condition can also manifest itself in less frequent ways, such as pustular, guttate, and erythrodermic psoriasis. About 50% of psoriasis patients report having pitted nails to some extent (Casale et al., 2021). Histologically, lesion psoriatic skin has a considerable epidermal thickness, cutaneous inflammatory cell infiltration, and an increase in the number of dilated blood vessels in the upper dermis. Due to its persistence and need for ongoing treatment, psoriasis is linked to a heavy disease burden and has a negative impact on patients' quality of life (M. G. Lebwohl et al. 2014). The wide range of psoriatic diseases, which include many psoriasis subtypes and psoriatic arthritis, have no identified treatments. Psoriasis is associated with high morbidity rates, and current therapies can have substantial negative side effects. Psoriasis and metabolic syndrome, type 2 diabetes, and atherosclerosis are strongly correlated, and these three conditions together account for the bulk of mortality in the Western world. Long-term therapy's financial burdens and the disease's social effects have a big impact on the health care system and society as a whole. The overall yearly direct and indirect expenses of psoriasis are over US $11 billion, with lost workdays accounting for 40% of the financial burden, according to the National Psoriasis Foundation, USA. Topical corticosteroids, vitamin D analogues, calcineurin inhibitors, Keratolytics, and coal tar are some of the topical treatments for mild psoriasis. Biologics (such as Etanercept, Adalimumab, Certolizumab, Infliximab, Ustekinumab, Secukinumab, and Ixekizumab) and small molecules (like apremilast) can be used to treat patients with moderate-to-severe illness. Several common systemic drugs, including as methotrexate (MTX), cyclosporine A, and retinoid, can be used to treat psoriasis (Armstrong and Read, 2020).
CARD14 modulates NF-kB-mediated responses in the skin. In order to gather data on a connection between psoriasis and various immune system loci, Elder and his colleagues assessed the SNP analyses of multiple significant studies in this field.

These loci included the TH17 pathway (IL12B, IL23A, IL23R, TRAF3IP2, TYK2), the innate immunity (NFκB and IFN) signalling pathways (TNFAIP3, TNIP1, NFKBIA, REL, TYK2, IFI1H), and the TH2 route (Fig. 2). The two main effects of the underlying patho-physiologic dysregulation in psoriasis are excessive keratinocyte proliferation and aberrant differentiation. The epidermal rete peg clearly lengthens and the epidermis thickens considerably histologically as a result of an increase in keratinocyte proliferation in the intermolecular epidermis. The following observations strongly support the idea that T lymphocytes have a role in pathogenesis: (i) immunotherapy that targets T cells or T cell cytokines like IL-17 clears psoriasis active plaques and (ii) Following intradermal infusion of antigen-activated T cells, transplanted nonlesional psoriatic skin in SCID mice develops into a psoriatic plaque.

Studies in the SCID mouse model have shown that lymphocytes triggered by substance P (SP) and nerve growth factor (NGF) may also produce psoriasis in nonlesional psoriatic skin grafts, in addition to the typical inflammatory mediators (Fig. 3). Accordingly, certain T cell subpopulations, in conjunction with their receptors, chemokines (Th1, Th17, and Th22), adhesion molecules, growth factors like NGF, and neuropeptides all collaborate to evolve into the distinct inflammatory and proliferative processes that are specific to psoriasis. Numerous studies have been conducted on the inflammatory infiltrates that affect the skin and joints. Both tissues exhibit detectable lymphocytic infiltrates in the sub lining layer stroma of the joint and the dermal papillae of the skin, respectively. This ratio is inverted in regions of the body where CD8+T cells are more prevalent, including the epidermis, synovial fluid compartment, and the enthesis. T cells, which predominately consist of CD4+ lymphocytes, are the most prominent lymphocytes in tissues. The potential that CD8+ T cells are in charge of the immune response in the skin and joints is increased by this differentiating CD8+ T cell tropism.

Human Leucocyte Antigen (HLA) Class Association in Psoriasis is true. Histological markers of plaque psoriasis include elongated epidermal rete pegs, parakeratosis, loss of the granular layer, suprapapillary thinning, spongiform Kojog pustules, dermal/epidermal CD3+T cell infiltrates, and epidermotropism of CD8+ T cells. The typical dermal and epidermal features of a plaque psoriasis may not match the histological characteristics of psoriatic subtypes.
Diagnosis of Psoriasis:
Psoriasis is diagnosed clinically by pattern recognition because there are no established diagnostic criteria for the condition. This calls for a comprehensive morphologic investigation of a skin lesion. Psoriasis has been divided into a variety of clinical phenotypes based on the characteristics of the cutaneous lesions and anatomical sites.

Psoriasis clinical phenotypes:
Psoriasis with plaques:
Nearly 90% of people with psoriasis have this kind, making it the most prevalent is sometimes referred to as psoriasis vulgaris. The lesion typically starts off as erythematous papules or macules that spread outside of the body before hardening into plaques. The lesions are distinguished by dry, rounded or oval plaques with distinct borders that are covered in loosely adhering silvery white scales. Despite the fact that psoriasis plaques can appear anywhere on the body, they often appear symmetrically dispersed over the elbows and knees, with the scalp possibly being the most commonly afflicted location (Madabhavi et al. 2020). The Koebner phenomenon is when new lesions develop in a...
psoriasis patient after acute cutaneous trauma. Another prominent characteristic of plaque psoriasis is the Auspitz phenomenon, in which a little breach of the lesion’s outermost layer causes pinpoint bleeding.

**Intestinal psoriasis:**
Spherical, erythematous exanthems that are generally less than 1 cm in size and spread centripetally throughout the trunk and extremities are the hallmark of intestinal psoriasis. The lesions are monomorphic, have droplet-like morphology (referred to as "gutta"), and are at the same evolutionary stage. After getting a streptococcal infection or an upper respiratory tract infection, children and teens frequently develop guttate psoriasis. The condition is often self-limiting, although a small number of people may develop persistent plaque psoriasis. It follows that the genetic similarity of chronic plaque psoriasis and guttate psoriasis, which have a high connection with the PSORS1 genetic locus, is not a surprise (Asumalahti *et al*., 2003).

**Psoriasis with pustules:**
Clusters of painful, sterile pustules with an underlying, blotchy, erythematous substrate are the hallmark of pustular psoriasis. Histologically, the lesions show intraepidermal micropustules and extensive dermal neutrophil infiltration. There are several ways to characterise pustular psoriasis. The two most well-known kinds are localised pustular psoriasis and generalised pustular psoriasis (Baker *et al*., 1968). Acrodermatitis continuous of Hallopeau and palmar pustulosis are two different types of localized pustular psoriasis. The pustular eruption of the fingers and toes distinguishes Acrodermatitis continuous from other skin conditions. The pustules and scaling that define palmoplantar pustular psoriasis are erythematous at the base. It often impacts the nails and is related to psoriasis. Plaque development is uncommon in palmoplantar pustulosis, but it is possible if psoriasis vulgaris is present as well. Generalized pustular psoriasis is a rare, aggressive, and unstable illness. According to study, 20% of people with persistent plaque psoriasis may eventually develop pustular lesions. Generalized pustular psoriasis patients frequently have severe illnesses, need hospitalization, and have to have their liver function, hypocalcaemia, and hydration well monitored. Pustular psoriasis may be cured with vigorous therapy and supportive care. Rarely, the first six months of pregnancy might see the development of impetigo herpetiformis, a form of pustular psoriasis (Wamalwa, 2017).

**Dermatologic psoriasis:**
Clinically, the majority of the body's surface is covered in generalised erythema. Erythrodermic psoriasis commonly occurs from inadequate management of pre-existing psoriasis, abrupt discontinuation of systemic therapy, such as corticosteroids, an unfavourable drug reaction, such as a lithium reaction, or an underlying systemic infection. Erythrodermic psoriasis may be easy to identify in patients who have previously experienced psoriasis. Airborne contact dermatitis, drug rash, Sezary syndrome, and pityriasis rubra pilaris should all be taken into consideration in the differential diagnosis of erythroderma since they can all be lethal. The presence of erythrodermic psoriasis in a patient with undiagnosed erythroderma may be indicated by nail changes. Additionally, a skin biopsy may help with both the diagnosis of psoriasis and the exclusion of the aforementioned conditions.

**Psoriasis phenotypes according to anatomical site involvement:**

**Psoriasis of the scalp:**
Psoriasis is known to often affect the scalp. Due of its appearance, scalp psoriasis at the hairline can significantly reduce quality of life. Choosing the best course of therapy, having trouble applying topical medications, and figuring out how to handle a severe case of the illness are all significant hurdles in controlling scalp psoriasis.
**Inverse and flexural psoriasis:**

Contrary to its preferred outer locations, such as the knees and elbows, psoriasis can appear on flexor surfaces and in skin folds, including the perineal, inframammary, axillary, inguinal, and intergluteal areas. Because they are wet, the psoriasis in these areas is less scaly than the plaque form.

**Platyplantar psoriasis:**

Nonpustular palmoplantar psoriasis is a potentially crippling condition marked by painful fissures and thick scales (Janagond et al., 2013). Systemic methotrexate and acitretin were assessed for their effectiveness and safety in treating psoriasis patients with substantial palmoplantar involvement.

**Psoriasis of the genitalia:**

Genital psoriasis can afflict people of any age, including infants and the elderly. Over one-third of psoriasis patients also have genital psoriasis. This particular kind of psoriasis requires special attention since it significantly affects both men and women's quality of life.

**Toenail psoriasis:**

Nails are frequently affected by psoriasis, and occasionally, the condition’s distinctive alterations can be identified. There are currently limited and usually unsuccessful treatment options for nail psoriasis. Onycholysis, or the detachment of the nail's proximal portion from the nail bed, is the most common nail abnormality, while pitting is the most blatant sign of psoriasis in the nails. To describe nail bed involvement, the terms "oil spots" or "orange-yellow patches" are frequently employed. Additionally, the nail plate may thicken, dystrophize, change color, or become yellow. Subungual hyperkeratosis is the accumulation of keratinous material beneath the nail plate.

**Treatment of Psoriasis:**

Decisions about the treatment of psoriasis should be based on an evaluation of the condition's severity, the existence of concomitant conditions, the requirement for referral to a specialist, and, if feasible, the identification of psoriasis trigger factors (Beyaert et al., 2013). IL-12/IL-23 (Ustekinumab), IL-17 (Secukinumab and Ixekizumab), and monoclonal antibodies that target tumour necrosis factor (infliximab, adalimumab, and Etanercept) are among the most recent biologic therapies for psoriasis (Nast et al., 2015; Gómez-García et al., 2017).

Glucocorticoids, vitamin D analogues, and phototherapy can all be used topically to treat mild to severe psoriasis. Treatment options for systemic psoriasis are frequently needed. Comorbid conditions like psoriasis arthritis are also very important when choosing a course of therapy. Advanced targeted biological medications have been developed in recent years as a result of a rapid development in psoriasis therapy. There are several conventional systemic treatments for psoriasis (Table 1), including methotrexate (MTX), cyclosporine A, and retinoid (Thorleifsdottir et al., 2017).

**Psoriasis therapies for mild cases:**

Although mild psoriasis has several different definitions, it typically affects less than 3% to 5% of the body's surface. Evaluation for psoriatic arthritis is the first step in the overall treatment strategy for psoriasis regardless of the severity of the condition.

**Corticosteroids Topical:**

Most people with mild or localised psoriasis receive their treatment mostly from topical corticosteroids. The anti-inflammatory, anti-proliferative, and locally vasoconstrictive actions of topical corticosteroids are caused by their suppression of the genes that produce pro-inflammatory cytokines. Given the proper dosage and patient compliance, topical corticosteroids are frequently effective in treating mild or localised psoriasis. The efficiency of topical corticosteroids varies depending on the class.
### Table 1: Drugs that can be used to treat psoriasis

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Drug</th>
<th>Mechanism</th>
<th>Route of Administration</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Methotrexate</td>
<td>Inhibition of dihydrofolate reductase prevents the production of purines and causes lymphocyte death.</td>
<td>S.C./Oral</td>
<td>Revicki et al. (2008)</td>
</tr>
<tr>
<td>2.</td>
<td>Cyclosporine</td>
<td>Inhibition of calcineurin results in a decrease in IL-2</td>
<td>Oral</td>
<td>Saurat et al. (2008), Maza et al. (2011)</td>
</tr>
<tr>
<td>3.</td>
<td>Acitretin</td>
<td>Retinoid receptor binding normalizes keratinocyte differentiation and proliferation</td>
<td>Oral</td>
<td>Lindqvist et al. (2018), Dogra and Yadav (2014)</td>
</tr>
<tr>
<td>4.</td>
<td>Fumarate</td>
<td>The pro-inflammatory Th1/Th17 response is switched to an anti-inflammatory/regulatory Th2 response with the aid of intracellular glutathione, Nrf2, NF-B, and HIF-1 regulation.</td>
<td>Oral</td>
<td>Coates and Helliwell (2016)</td>
</tr>
<tr>
<td>5.</td>
<td>Etanercept</td>
<td>TNF-R-mimicking dimeric human fusion protein</td>
<td>S.C.</td>
<td>West et al. (2017)</td>
</tr>
<tr>
<td>6.</td>
<td>Infliximab</td>
<td>soluble and trans membrane forms of TNF are both recognized by the monoclonal antibody chimeric IgG1.</td>
<td>I.V.</td>
<td>Zhang et al. (2018)</td>
</tr>
<tr>
<td>7.</td>
<td>Certolizumab</td>
<td>TNF-specific humanized monoclonal antibody with a polyethylene glycol-conjugated Fc part</td>
<td>S.C.</td>
<td>Turkmen and Dogan (2021)</td>
</tr>
<tr>
<td>8.</td>
<td>Ustekinumab</td>
<td>The p40 protein component, which is used by both IL-12 and IL-23 cytokines, is specifically bound by a human IgG1k monoclonal antibody known as IL-12/IL-23 p40.</td>
<td>S.C.</td>
<td>Savage et al. (2015)</td>
</tr>
<tr>
<td>9.</td>
<td>Tildrakizumab</td>
<td>Humanized IgG1 binds to the p19 component of IL-23 to specifically inhibit it.</td>
<td>S.C.</td>
<td>Banaszczynk (2019)</td>
</tr>
<tr>
<td>10.</td>
<td>Guselkumab</td>
<td>IL-23's p19 component is particularly inhibited by the human immunoglobulin G1 lambda (IgG1) monoclonal antibody.</td>
<td>S.C.</td>
<td>Nogueira and Torres (2019)</td>
</tr>
<tr>
<td>11.</td>
<td>Risankizumab</td>
<td>Monoclonal humanized IgG1 antibody that targets the p19 subunit to inhibit interleukin-23</td>
<td>S.C.</td>
<td>Huang and Tsai (2020)</td>
</tr>
<tr>
<td>12.</td>
<td>Secukinumab</td>
<td>Monoclonal human IgG1 antibody against IL-17A</td>
<td>S.C.</td>
<td>Berg et al. (2021)</td>
</tr>
<tr>
<td>13.</td>
<td>Ixekizumab</td>
<td>Monoclonal humanized immunoglobulin G4 antibodies bind and neutralize IL-17A very specifically.</td>
<td>S.C.</td>
<td>Ruggiero et al. (2022)</td>
</tr>
<tr>
<td>14.</td>
<td>Brodalumab</td>
<td>IgG2 monoclonal antibody against IL-17RA that is human</td>
<td>S.C.</td>
<td>Kim Papp et al. (2014)</td>
</tr>
</tbody>
</table>
Skin-Applied Vitamin D Analogues:

Topical vitamin D analogues work by attaching to the vitamin D receptors on T cells and keratinocytes. As a result, keratinocyte differentiation is promoted and keratinocyte proliferation is suppressed. The three types of topical vitamin D analogues used in the USA are calcitriol alone, calcitriol coupled with another calcitriol, or calcipotriene. As long as the patient has healthy renal function, a variety of topical vitamin D analogues can be employed.

Inhibitors of Calcineurin Topical:

Topical calcineurin inhibitors stop the generation of IL-2 and IFN-γ, which prevents T cell activation. Tacrolimus and pimecrolimus are two examples of topical calcineurin inhibitors that are regularly used to treat psoriasis in intertriginous and face regions without the unfavourable side effect of skin shrinkage associated with extended therapy. Skin irritation is a common side effect, especially in severely inflamed lesions.

Therapeutic Keratolytics:

Topical tazarotene and salicylic acid are examples of Keratolytics agents. A topical retinoid called tazarotene slows keratinocyte growth and aids in removing the plaque's thick scales. After 12 weeks, at least 63% of individuals may have a 50% improvement in their psoriasis. Burning and irritation are two common side effects that can be decreased by using a lower dose, a cream formulation, an alternate day of treatment, or using it in conjunction with topical corticosteroids (Lebwohl et al., 2019).

Specific Phototherapy:

Exposure to particular light wavelengths constitutes phototherapy, often known as light therapy. Plaque psoriasis sufferers have long been treated with phototherapy. Phototherapy, unlike sunshine, offers certain wavelengths that are beneficial for treating psoriasis while reducing emission of wavelengths linked to cancer (Wong et al., 2020).

Treatments for Moderate to Severe Psoriasis:

There is substantial disagreement over what constitutes moderate to severe psoriasis. Others estimate that 5% to 10% of the body's surface area is affected by mild psoriasis. When psoriasis affects 3% to 10% of the body's surface, some doctors describe the condition as moderate. 10% or more of the body's surface area being affected is often considered to be severe psoriasis. Systemic treatments are often used to treat patients with moderate to severe psoriasis (Armstrong et al., 2020).

Phototherapy:

With the development of biologics, phototherapy for moderate to severe psoriasis has become less common. The three primary forms of phototherapy used to treat psoriasis are broadband UV-B, narrowband UV-B, and psoralen with UV-A (PUVA). Narrowband UV-B therapy is typically chosen over broadband therapy because it is more effective. It is also preferred for application because narrowband UV-B has a superior safety profile than PUVA (Wong et al., 2013; Zhang et al., 2018).

UV-B:

UV-B exposure reduces DNA synthesis, which causes keratinocyte death and lower T cell production of proinflammatory cytokines. Both the narrowband (311 nm) and the broadband (290-320 nm) wavelengths of UV-B phototherapy can be utilized to treat plaque psoriasis. Initial therapy is often given three times per week in an office setting or at home. To maintain efficacy, treatment frequency can be lowered to twice weekly; eventually, depending on the patient's reaction, it may be further reduced (Armstrong et al., 2020).

PUVA:

A psoralen, such as methoxalen, is used in PUVA therapy and is used topically or orally before UV-A (320-400 nm) radiation. Psoralen is intercalated into DNA in order to inhibit DNA synthesis. Patients normally get oral PUVA two to three times a week during the initial phase of treatment, until the psoriasis is completely or
Table 2: List of non-drug therapies for various illnesses

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Kind of treatment</th>
<th>Explanation</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Dietary</td>
<td>Components include milk, butter, mung beans, spinach, pumpkin, Prunus dulcis, grape (Vitis vinifera), pomegranate juice, plum juice, tamarind, and fig (ficus carica). Other components include non-alcoholic beer, oxyymel, and Vitis vinifera.</td>
<td>Ghaffari et al. (2022), Mashhadi et al. (2022)</td>
</tr>
<tr>
<td>2.</td>
<td>Avoiding</td>
<td>Spicy, really salty and sour meal lentils, eggplant, horse, duck, goat, and rabbit Garlic and onion, dried and salted pork, mushrooms, cabbage Game meat, dried fish, old cheese, hard-boiled eggs, Sugar, aged wine</td>
<td>Tsapenko (2021)</td>
</tr>
<tr>
<td>3.</td>
<td>Sleep and awareness</td>
<td>Since sleeplessness can exacerbate a condition, treatment is essential. Consuming Ma'aljobon, sweet almonds, and dishes that are humidifying— Cooking poultry, fish, or yeanling with squash, spinach, lettuce, and Viola odorata oil is a healthful option.</td>
<td>Van Renterghem (2022)</td>
</tr>
<tr>
<td>4.</td>
<td>Air and climate</td>
<td>The symptoms of the illness are made worse by extremely hot, cold, and dry environments. When the humidity increases, the symptoms get better.</td>
<td>Hashemi and Raza (2009)</td>
</tr>
<tr>
<td>5.</td>
<td>Exercise and activity</td>
<td>The symptoms of the condition are made worse by exercise and vigorous physical and sexual activity. Therefore, it's important to balance these activities, nearly completely gone; thereafter, the frequency of treatment gradually reduces.</td>
<td>Maza et al. (2011)</td>
</tr>
</tbody>
</table>

Non-pharmacological treatments:

A list of non-drug therapies for various illnesses was provided (Table 2), including food and lifestyle modifications, leech therapy, venesection, and phlebotomy.

Conclusion

Psoriasis is a complicated disease with a range of clinical manifestations. Individualized treatment program that are catered to the patient’s particular needs and include topical medicines, phototherapy, systemic drugs, and biologics are necessary for effective care. The degree of psoriasis, co-morbidities, and patient preferences should all be taken into account when selecting a course of treatment. Holistic treatment is essential in addition to medical measures. Integral parts of psoriasis therapy include dietary changes, stress reduction, and psychological support. A nutritious diet and stress management practices should be discussed with patients as an adjunct to medical care. Psoriatic arthritis is a major issue since it is one of much comorbidity linked to psoriasis. In order to stop future joint deterioration and enhance the patient’s overall quality of life, early detection and treatment are crucial. Regular monitoring and cooperation between dermatologists and rheumatologists are crucial in this context. This in-depth analysis emphasizes the complexity of psoriasis and the value of a multifaceted strategy for both diagnosis and therapy. It focuses on the importance of individualized care, comprehensive treatment, and early intervention for problems, patient education, and a persistent goal of raising the patient’s quality of life. These guidelines can help medical practitioners better handle the problems caused by psoriasis and improve the well-being of persons who suffer from this chronic skin condition.

References


